Molecular forms of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with senile dementia of the Alzheimer type

Biological Psychiatry

Volumn 41, Issue 11, 1997, Pages 1124-1130

  Strittmatter, M ^a   Cramer, H ^b   Reuner, C ^b   Strubel, D ^c   Hamann, G ^a   Schimrigk, K ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

CSF; dementia; SDAT; somatostatin; somatostatin 14

Indexed keywords

NEUROLEPTIC AGENT; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RADIOIMMUNOASSAY; SENILE DEMENTIA;

AGED; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COGNITION DISORDERS; CROSS REACTIONS; FEMALE; HUMANS; MALE; MOLECULAR WEIGHT; SOMATOSTATIN;

EID: 0031003207     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00211-9     Document Type: Article

References (37)

1. Arai H, Ichimiya Y, Kosaka K, Moroji T, Iizuka R (1992): Neurotransmitter changes in early- and late-onset Alzheimertype dementia. Prog Neuropsychopharmacol Biol Psychiatry 16(6):883-890.
2. Baker GB, Reynolds GP (1989): Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata. Neurosci Lett 100:335-339.
3. Beal MF, Uhl G, Masurek MF, Kowall N, Martin JB (1986a): Somatostatin: Alterations in the central nervous system in neurological diseases. In Martin JB and Marchas JD (eds) Neuropeptide in Neurological and Psychiatric Disease New York: Raven Press, pp 215-254.
4. Beal MF, Uhl G, Masurek MF, Kowall N, Martin JB (1986b): Somatostatin: Alterations in the central nervous system in neurological diseases. In Martin JB and Marchas JD (eds) Neuropeptide in Neurological and Psychiatric Disease New York: Raven Press, pp 215-254.
5. Beal MF, Growdon JH, Mazurek MF, Martin JB (1986c): CSF somatostatin-like immunoreactivity in dementia. Neurology 36:294-297.
6. Bisette G, Myers B (1992): Minireview: Somatostatin in Alzheimer's disease and depression. Life Sci 51:1389-1410.
7. Candy JM, Cascoigne AD, Biggins JA, Smith AI, Perry RH, Perry K, Mc Permatt, Edwardson A (1985): Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer's disease. J Neurol Sci 71:315-323.
8. Cervera-Pierot P, Hirsch EC, Javoy-Agid F, Ransmayr G, Hauw JJ, Agid J (1992): Hippocampal and parahippocampal somatostatin 28 and neuropeptide Y containing neurons in Alzheimer's disease. Dementia 3:282-298.
9. Chan-Palay V, Asan E (1989): Alterations in catecholamine neurons of the locus coerulus in senile dementia of the Alzheimer's disease. J Comp Neurol 287:373-392.
10. Constantinidis J, Bouras C, Vallet PG (1988): Neuropeptides in Alzheimer's disease and in Parkinson's disease. Mt Sinai J Med 55:102-155.
11. Cramer H, Schaudt D, Rissler K, Strubel D, Warter JM, Kuntzmann F (1985): Somatostatin-like immunoreactivity and substance P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus. J Neurol 38:346-351.
12. Davies CA, Morroll DR, Prinja D, Mann DMA, Gibbs A (1990): A quantitative assessment of somatostatin-like neuropeptide-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease. J Neurol Sci 96:59-73.
13. Dawbarn D, Rossor MN, Mountjoy CQ, Roth M, Emson P (1986): Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of the Alzheimer type. Neurosci Lett 70:154-159.
14. Dournaud P, Cervera-Pierot P, Hirsch E, Javoy-Agid F, Kordon CL, Agid Y, Epelbaum J (1994): Somatostatin messenger RNA-containing neurons in Alzheimer's disease: An in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex. Neurosci 61(4):755-764.
15. Epelbaum J, Ruberg M, Moyse E, Javoy-Agid F, Dubois B, Agid Y (1983): Somatostatin and dementia in Parkinson's disease. Brain Res 278:376-379.
16. Gaspar P, Duyckaerts C, Febvret A, Benoit R, Beck B, Berger B (1988): Subpopulations of Somatostatin 28-immunoreactive neurons display different vulnerability in senile dementia of Alzheimer type. Brain Res 490:1-13.
17. Gattaz WF, Rissler K, Gattaz D, Cramer H (1986): Effects of haloperidol on somatostatin-like immunoreactivity in the CSF of schizophrenic patients. Psychiatry Res 17:1-6.
18. Gaykema RP, Gaal G, Traber J, Hersh LB, Luiten PG (1991): The basal forebrain cholinergic system: Efferent and afferent connectivity and long-term effects of lesions. Acta Psychiatr Scand Suppl 366:14-26.
19. Gottfries CG (1985): Alzheimer's disease and senile dementia: Biochemical characteristics and aspects of treatment. Psychopharmacology 86:245-252.
20. Hargrove JL, Schmidt FH (1989): The role of mRNA and protein stability in gene expression. Fedn Proc Fedn Am Socs Exp Biol 3:2360-2370.
21. Kramer M (1980): The raising pandemic of mental disorders and associated chronic diseases and disabilities. Acta Psychiat Scand 62:382-397.
22. Leake A, Ferrier IN (1993): Alterations in aging and disease. Pathophysiology and potential for clinical intervention. Drugs Aging 3(5):408-427.
23. Leake A, Perry EK, Perry RH, Jabeen S, Fairbairn AF, Mc Keith IG, Ferrier IN (1991): Neocortical concentrations of neuropeptides in senile dementia of the Alzheimer and Lewy body type: Comparison with Parkinson's disease and severity correlations. Biol Psychiatry 29(4):357-364.
24. Mc Geer PL, Mc Geer EG, Suzuki J, Dolman CE, Nagai T (1984): Aging, Alzheimer's disease and the cholinergic system of the basal forebrain. Neurology 34:741-745.
25. Morrison JH, Rogers J, Scherr S, Benoit R, Bloom FE (1985): Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients. Nature 314:90-92.
26. Pierotti AR, Harmar AJ, Simpson J, Yates CM (1985): High molecular weight forms of somatostatin are reduced in Alzheimer's disease and Down's syndrome. Neurosci Lett 63:141-146.
27. Procter AW, Francis PT, Stratmann GC, Bowen DM (1992): Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. Neurochem Res 17(9):917-922.
28. Radke JM, Mc Lennan AJ, Vincent SR, Fibiger HC (1988): Comparison between long-term haloperidol administration on somatostatin and substance P concentrations in the rat brain. Brain Res 445:55-60.
29. Reisberg B, Ferris SH, Mony D, De Leon J, Crook WF (1982): The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 139:1136-1139.
30. Rissler K, Cramer H, Schaudt D, Strubel D, Gattaz WF (1986): Molecular size distribution of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with degenerative brain disease. Neurosci Res 3:213-225.
31. Soerensen KV, Christensen SE, Hansen AP, Ingerslev J, Pedersen E, Orskov H (1981): The origin of cerebrospinal fluid somatostatin: Hypothalamic or disperse central nervous system secretion. Neuroendocrinology 32:335-338.
32. Soininen HS, Jolkkonen JT, Reinikainen KJ, Halonen TD, Riekkinen PJ (1984): Reduced cholinesterase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Sci 63:167-172.
33. Strittmatter M, Cramer H (1992): Parkinson's disease and dementia: clinical and neurochemical correlations. Neuroreport 3:413-416.
34. Van Hoesen GW, Hyman BT, Damsio AR (1991): Enthorinal cortex pathology in Alzheimer's disease. Hippocampus 1:1-8.
35. Weber SJ, Louis RB, Trombley L, Bisette G, Davies P, Davies TP (1992): Metabolic half-life of somatostatin and peptidase activities are altered in Alzheimer's disease. J Gerontol 47(1):B18-25.
36. Whitehouse PJ (1992): Alzheimer's disease: Relationship of cognition and behaviour to neurochemistry. Int Psychogeriatr 4(1)71-78.
37. Whitehouse PJ, Unnerstall JR (1988): Neurochemistry of dementia. Eur Neurol 28:36-41.